Who is sponsoring NCT05526833?

NCT05526833 is sponsored by Columbia University.

What drugs are being tested in NCT05526833?

Interventions in NCT05526833: Repetitive Transcranial Magnetic Stimulation (rTMS).

What condition does NCT05526833 study?

NCT05526833 studies Schizophrenia and Related Disorders.

Is NCT05526833 still recruiting?

NCT05526833 is currently terminated. Last updated 16 February 2024.

Are results published for NCT05526833?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-02-16 · How we verify

NCT05526833

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Extension Protocol for Patients Who Previously Completed the TMS Pilot Study

Terminated NA Results posted Last updated 16 February 2024

What this trial tests

NA trial testing Repetitive Transcranial Magnetic Stimulation (rTMS) in Schizophrenia and Related Disorders in 3 participants. Terminated before completion.

Timeline

12 September 2022

Primary endpoint
24 January 2023

26 January 2023

Quick facts

Lead sponsor	Columbia University
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	12 September 2022
Primary completion	24 January 2023
Estimated completion	26 January 2023
Sites	1 location across United States

Drugs / interventions tested

Repetitive Transcranial Magnetic Stimulation (rTMS)

Conditions studied

Schizophrenia and Related Disorders — all drugs for Schizophrenia and Related Disorders →

Sponsor

Columbia University

Who can join

Adults 22 to 55, any sex, with Schizophrenia and Related Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label extension study to continue to evaluate the safety, tolerability and efficacy of the Repetitive Transcranial Magnetic Stimulation (rTMS) in subjects with schizophrenia or schizoaffective disorder who previously completed the treatment study of the protocol #8116 (NCT05319080). Protocol #8116 investigates the clinical efficacy of open-label individualized MRI-guided TMS applied to the left temporoparietal junction (TPJ) in schizophrenia patients. Participating patients who have completed the 4-week project #8116 can be screened for eligibility for this extension study in which they will continue treatment/assessment. They will be divided into three groups (non-responders, partial responders, or full responders) based on a reduction in the Auditory Hallucination Rating Scale (AHRS) scores from the study #8116.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Repetitive Transcranial Magnetic Stimulation (rTMS)

Trials testing the same drug.

NCT07454954 — The Effect of Blood Flow Restriction Training Combined With Transcranial Magnetic Stimulation on Limb Function in Hemipl · NA · not yet recruiting
NCT06953596 — Transcranial Magnetic Stimulation to Treat Prolonged Grief Disorder · NA · not yet recruiting
NCT06991062 — Bayesian Neurobehavioral Phenotyping: From Mechanism Identification to Personalized Neuromodulation Treatments. R61 PHAS · NA · recruiting
NCT05426967 — rTMS for Military TBI-related Depression · NA · recruiting
NCT06639594 — Feasibility of Accelerated, Personalized rTMS as an Adjuvant for Impulse Control Disorders: a Pilot Study · Phase 1 · recruiting

Other recruiting trials for Schizophrenia and Related Disorders

Currently open trials in the same condition.

NCT07378150 — Clay Therapy in Schizophrenia Patients · NA · recruiting
NCT07119268 — SPARK Healthy Sleep · NA · recruiting
NCT05603104 — Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First- · Phase 3 · recruiting
NCT02916810 — Alternative Stimulation Mode and Location for Auditory Hallucination Neuromodulation Treatment · NA · recruiting
NCT06426134 — Ketosis Impact on Signs & Symptoms of Schizophrenia and Bipolar disorderS · NA · recruiting

Other Columbia University trials

Trials by the same sponsor.

NCT06558422 — Human Models of Selective Insulin Resistance: Pancreatic Clamp · Phase 1 · not yet recruiting
NCT07264582 — HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking · NA · not yet recruiting
NCT05992415 — Know Your Pressures NYC · NA · not yet recruiting
NCT05645211 — The AgRP and GH/IGF-1 Axis in Children · not yet recruiting
NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05526833 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Columbia University
Last refreshed: 16 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05526833.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing